Advertisement

Gastric Cancer pp 183-191 | Cite as

Gastric Cancer Prevention Using Helicobacter pylori Eradication in Japan

  • Masahiro AsakaEmail author
Chapter
  • 652 Downloads

Abstract

The annual number of deaths from gastric cancer is approximately 50,000, and there has been no change over the last 50 years in Japan. All efforts have been directed toward improving the detection of early gastric cancer by barium X-ray and endoscopy, since early cancer has a good prognosis, resulting in Japan having the best diagnostic capability for early gastric cancer worldwide.

H. pylori eradication therapy for chronic gastritis achieved the world’s first coverage by the Japanese national health insurance scheme in 2013, making a dramatic decrease of gastric cancer-related deaths more realistic. Combining H. pylori eradication therapy with endoscopic surveillance can prevent the development of gastric cancer. Even if gastric cancer develops, most patients are likely to be diagnosed while it is at an early stage, possibly resulting in a large decrease of gastric cancer deaths.

Approximately 1.6 million prescriptions for H. pylori eradication therapy were written annually. Gastric cancer deaths fell each year: 48,427 in 2013, 47,903 in 2014, 46,659 in 2015, and 45,509 in 2016, showing a significant decrease after expansion of insurance coverage for H. pylori eradication therapy (P < 0.0001). Prescriptions for H. pylori eradication therapy increased markedly after approval of the gastritis indication by the national health insurance scheme and were associated with a significant decrease in gastric cancer deaths.

Keywords

Gastric cancer prevention Helicobacter pylori (H. pylori) H. pylori-associated gastritis Elimination of gastric cancer 

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefGoogle Scholar
  2. 2.
    Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273–5.PubMedGoogle Scholar
  3. 3.
    Blaser MJ. Helicobacter pylori and the pathogenesis of gastroduodenal inflammation. J Infect Dis. 1990;161:626–33.CrossRefGoogle Scholar
  4. 4.
    Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. Helicobacter. 2001;6:294–9.CrossRefGoogle Scholar
  5. 5.
    Asaka M, Takeda H, Sugiyama T, Kato M. What role does Helicobacter pylori play in gastric cancer? Gastroenterology. 1997;113(Suppl):S56–60.CrossRefGoogle Scholar
  6. 6.
    Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer. 2013 15;132:1272–6.CrossRefGoogle Scholar
  7. 7.
    International Agency for Research on Cancer. World Health Organization: schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risk Hum. 1994;61:177–241.Google Scholar
  8. 8.
    Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008;372:392–7.CrossRefGoogle Scholar
  9. 9.
    Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–9.CrossRefGoogle Scholar
  10. 10.
    Yoon H, Kim N, Lee HS, Shin CM, Park YS, Lee DH, et al. Helicobacter pylori-negative gastric cancer in South Korea: incidence and clinicopathologic characteristics. Helicobacter. 2011;16:382–8.CrossRefGoogle Scholar
  11. 11.
    Hamashima C, Shibuya D, Yamazaki H, Inoue K, Fukao A, Saito H, et al. The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2008;38:259–67.CrossRefGoogle Scholar
  12. 12.
    Trends in site-specific crude mortality rate 1965–2014. Cancer Statistics in Japan-2015, Tokyo, Japan, 2015. p. 39. http://ganjoho.jp/data/reg_stat/statistics/brochure/2015/cancer_statistics_2015.pdf.
  13. 13.
    Tsuda M, Asaka M, Kato M, Matsushima R, Fujimori K, Akino K, Kikuchi S, Lin Y, Sakamoto N. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017.  https://doi.org/10.1111/hel.12415.CrossRefGoogle Scholar
  14. 14.
    Inoue K, Fujisawa T, Haruma K. Assessment of degree of health of the stomach by concomitant measurement of serum pepsinogen and serum Helicobacter pylori antibodies. Int J Biol Markers. 2010;25:207–12.CrossRefGoogle Scholar
  15. 15.
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.CrossRefGoogle Scholar
  16. 16.
    Miehlke S, Kirsch C, Dragosics B, et al. Helicobacter pylori and gastric cancer: current status of the Austrian Czech German gastric cancer prevention trial (PRISMA Study). World J Gastroenterol. 2001;7:243–7.CrossRefGoogle Scholar
  17. 17.
    Whiting JL, Sigurdsson A, Rowlands DC, et al. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut. 2002;50:378–81.CrossRefGoogle Scholar
  18. 18.
    Arima N, Adachi K, Katsube T, et al. Predictive factors for metachronous recurrence of early gastric cancer after endoscopic treatment. J Clin Gastroenterol. 1999;29:44–7.CrossRefGoogle Scholar
  19. 19.
    Nasu J, Doi T, Endo H, Nishina T, et al. Characteristics of metachronous multiple early gastric cancers after endoscopic mucosal resection. Endoscopy. 2005;37:990–3.CrossRefGoogle Scholar
  20. 20.
    Maehata Y, Nakamura S, Fujisawa K, et al. Long-term follow-up study about preventive effect of H. pylori eradication for the incidence of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2012;75:39–46.CrossRefGoogle Scholar
  21. 21.
    Kato M, Asaka M, Kikuchi S. Long-term follow-up study about preventive effect of H. pylori eradication for the Incidence of metachronous gastric cancer after endoscopic resection of primary early gastric cancer. Gastroenterology. 2012;142(Suppl 1):S3.CrossRefGoogle Scholar
  22. 22.
    Harvard Report on Cancer Prevention. Volume 1: Causes of human cancer. Cancer Causes Control. 1996;7 Suppl 1:S3–59.Google Scholar
  23. 23.
    Olsen JH, Andersen A, Dreyer L, et al. Summary of avoidable cancers in the Nordic countries. APMIS Suppl. 1997;76:141–6.CrossRefGoogle Scholar
  24. 24.
    Number of incidence by cancer site 2007. Cancer statistics in Japan-2012, Tokyo, Japan; 2012. p. 15.Google Scholar
  25. 25.
    Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter. 2010;15:1–20.CrossRefGoogle Scholar
  26. 26.
    Blaser MJ. Gastric Campylobacter-like organism, gastritis, and peptic ulcer diseases. Gastroenterology. 1987;93:371–83.CrossRefGoogle Scholar
  27. 27.
    Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol. 2014;49:1–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Health Sciences University of HokkaidoTobetsu-choJapan

Personalised recommendations